Clinical Trial Update: A Safety and Efficacy Trial of Amplimexon Plus Taxotere in Metastatic Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 safety and efficacy trial of Amplimexon in combination with Taxotere for metastatic non-small cell lung cancer was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amplimexon
• Taxotere (docetaxel)

Snippet

Sponsor: AmpliMed Corporation | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: WITHDRAWN